CA2138124A1 - Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity - Google Patents

Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity

Info

Publication number
CA2138124A1
CA2138124A1 CA002138124A CA2138124A CA2138124A1 CA 2138124 A1 CA2138124 A1 CA 2138124A1 CA 002138124 A CA002138124 A CA 002138124A CA 2138124 A CA2138124 A CA 2138124A CA 2138124 A1 CA2138124 A1 CA 2138124A1
Authority
CA
Canada
Prior art keywords
leu
mammal
group
alkyl
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002138124A
Other languages
English (en)
French (fr)
Inventor
David D. Eveleth, Jr.
Gary Lynch
James C. Powers
Raymond T. Bartus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortex Pharmaceuticals Inc
Ezra C Lundahl Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2138124A1 publication Critical patent/CA2138124A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002138124A 1992-06-24 1993-06-24 Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity Abandoned CA2138124A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US90380092A 1992-06-24 1992-06-24
US3499693A 1993-03-16 1993-03-16
US7260993A 1993-06-01 1993-06-01
US07/903,800 1993-06-01
US08/034,996 1993-06-01
US08/072,609 1993-06-01

Publications (1)

Publication Number Publication Date
CA2138124A1 true CA2138124A1 (en) 1994-01-06

Family

ID=27364781

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002138124A Abandoned CA2138124A1 (en) 1992-06-24 1993-06-24 Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity

Country Status (5)

Country Link
EP (1) EP0650368A1 (de)
JP (1) JPH09500087A (de)
AU (1) AU4544993A (de)
CA (1) CA2138124A1 (de)
WO (1) WO1994000095A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541290A (en) * 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
AU3935895A (en) * 1994-11-24 1996-06-17 Takeda Chemical Industries Ltd. Alpha-ketoamide derivatives as cathepsin l inhibitor
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5827877A (en) * 1995-09-14 1998-10-27 Cephalon, Inc. Ketomethylene group-containing cysteine and serine protease inhibitors
US5723580A (en) * 1995-09-14 1998-03-03 Cephalon, Inc. Ketomethylene group-containing aldehyde cysteine and serine protease inhibitors
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
KR19990067184A (ko) 1995-10-30 1999-08-16 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 프로테아제 억제제
DE69637307T2 (de) * 1995-11-28 2008-02-28 Cephalon, Inc. Aus d-aminosäuren abgeleitete cystein-und serinproteasehemmer
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
DE19642591A1 (de) * 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
US6303579B1 (en) 1996-10-31 2001-10-16 Alcon Laboratories, Inc. Use of calpain inhibitors to treat ocular neural pathology
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
AU721620B2 (en) * 1996-12-11 2000-07-13 Basf Aktiengesellschaft Novel ketobenzamides and their use
JP2002161051A (ja) * 1996-12-24 2002-06-04 Fujisawa Pharmaceut Co Ltd 脳虚血性疾患等の治療剤
SK14512000A3 (sk) 1998-04-20 2001-04-09 Basf Aktiengesellschaft Substituované amidy, ich príprava a použitie
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
WO1999054305A1 (de) 1998-04-20 1999-10-28 Basf Aktiengesellschaft Heterocyclisch substituierte amide als calpainhemmer
DE19818614A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
US6841537B1 (en) 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US6841538B1 (en) * 1998-04-22 2005-01-11 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and radio therapy
AU762986B2 (en) * 1998-04-22 2003-07-10 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and conventional drugs
EP1080074B1 (de) 1998-05-25 2006-11-08 Abbott GmbH & Co. KG Heterocyclische substituierte Amide, deren Herstellung und Verwendung
DE19847422C1 (de) * 1998-10-14 2000-01-13 Forschungszentrum Juelich Gmbh Chinese-Hamster-Ovary-Zellen zur Produktion von Proteinen
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2001034600A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
AU2001243441B2 (en) 2000-03-21 2004-11-25 Smithkline Beecham Corporation Protease inhibitors
MXPA03000626A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
CN102372764A (zh) 2000-07-21 2012-03-14 先灵公司 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
GB0106051D0 (en) * 2001-03-12 2001-05-02 Isis Innovation Diagnostic screens for alzheimer's disease
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US6610874B2 (en) 2001-09-28 2003-08-26 Pcbu Services, Inc. Processes and compositions for the production of chiral amino-nitriles
JP2005515254A (ja) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション カテプシンｋ阻害剤として有用なシクロアルキルケトアミド誘導体
DE602004023873D1 (de) 2003-12-12 2009-12-10 Senju Pharma Co Verwendung davon
EA017874B1 (ru) * 2005-03-21 2013-03-29 Вайробей, Инк. Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз
GB2467562A (en) * 2009-02-06 2010-08-11 Summit Corp Plc Dual calpain-ROS inhibitors
WO2013067415A1 (en) * 2011-11-02 2013-05-10 Tufts University Identification and use of protease inhibitors to treat or prevent sickle cell disease
CN102988336A (zh) * 2012-05-17 2013-03-27 中国人民解放军第二军医大学 Tpck用于制备抗晶状体混浊产品的用途
JP6533580B2 (ja) * 2014-09-08 2019-06-19 ランドステイナー ジェンメド、エセ．エレ．Ｌａｎｄｓｔｅｉｎｅｒ Ｇｅｎｍｅｄ， Ｓ．Ｌ． ジペプチジルケトアミド化合物ならびに脂肪蓄積の治療および／または予防のためのそれらの使用
JP6501353B2 (ja) * 2015-05-07 2019-04-17 国立大学法人山口大学 ＳＰＣ／Ｆｙｎ／Ｒｈｏキナーゼシグナル伝達経路の阻害剤
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
WO2018009417A1 (en) 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
SG11202008773PA (en) * 2018-03-28 2020-10-29 Blade Therapeutics Inc Method of treating fibrotic disease
AU2019242387A1 (en) * 2018-03-28 2020-11-19 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2023165334A1 (zh) * 2022-03-01 2023-09-07 成都威斯克生物医药有限公司 酮酰胺类衍生物及其制药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US4771123A (en) * 1986-03-11 1988-09-13 Enzyme Systems Products, Inc. Peptide thioneamides as selective substrates for cysteine proteases
NZ223148A (en) * 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5189144A (en) * 1989-04-28 1993-02-23 Takara Shuzo Co., Ltd. Human calpastatin-like polypeptide

Also Published As

Publication number Publication date
EP0650368A1 (de) 1995-05-03
WO1994000095A2 (en) 1994-01-06
AU4544993A (en) 1994-01-24
JPH09500087A (ja) 1997-01-07
WO1994000095A3 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
CA2138124A1 (en) Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
AU667463B2 (en) Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
US5444042A (en) Method of treatment of neurodegeneration with calpain inhibitors
US5610297A (en) Peptides ketoamides
DE69528888T3 (de) Regulation der NF-KB Aktivität durch Proteasomen
US6548477B1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US5693617A (en) Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
EP0564561A1 (de) Peptid-ketoamide, -ketosäuren und ketoester
JP4439111B2 (ja) ジペプチドのアポトーシスインヒビターおよびそれらの使用
US5763576A (en) Tetrapeptide α-ketoamides
DE10143840A1 (de) Neue Inhibitoren der Dipeptidylpeptidase I
JP2004531466A (ja) 血管新生を調節するための治療薬およびその使用方法
EP0356223A2 (de) HIV-Protease-Inhibitoren für die Behandlung von AIDS
KR19990022395A (ko) 가역성 시스테인 프로테아제 억제제
US6235929B1 (en) Tripeptide α-ketoamides
US7056947B2 (en) Aza-peptide epoxides
AU2005214388A1 (en) Propenoyl hydrazides
WO1999054317A1 (en) Cysteine protease inhibitors
JP2002508321A (ja) 抗腫瘍薬としての使用のための多触媒性プロテアーゼ阻害剤
KR20050009702A (ko) 메티오닌 아미노펩티다제-2 저해제 및 이의 이용방법
Kang et al. Recent developments of cathepsin inhibitors and their selectivity
JP2003502442A (ja) セリンエラスターゼの活性を阻害する方法及び化合物
JP6326232B2 (ja) 関節症の処置のためのアミノスタチン誘導体
AU2378299A (en) Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
AU654834C (en) Peptides ketoamides, ketoacids, and ketoesters

Legal Events

Date Code Title Description
FZDE Dead